Precision filter infusion sets market seen reaching $5.81 billion by 2030

The Business Research Company says the global precision filter infusion sets market will rise from $4.08 billion in 2025 to $5.81 billion by 2030, driven by safer intravenous care, rising cancer treatment use and more home-based healthcare. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Precision filter infusion sets are used to remove particulates, air bubbles and contaminants from intravenous fluids before they reach patients. - The market’s growth reflects higher demand for safer infusion therapy in hospitals, cancer care and home-based treatment settings. - The segment also tracks broader pressure on healthcare systems to reduce infection risk and improve drug delivery accuracy.

What happened: - The Business Research Company released its 2026 market report on precision filter infusion sets on July 21, 2026. - The report estimates the market will grow from $4.08 billion in 2025 to $4.37 billion in 2026. - The report forecasts the market will reach $5.81 billion by 2030. - The report puts the market’s CAGR at 7.2% from 2025 to 2026 and 7.4% from 2026 to 2030. - Download a free sample of the report. - View the full market report.

The details: - The report cites hospital-acquired infection concerns, higher demand for intravenous drug administration, healthcare infrastructure expansion, early adoption of disposable medical devices and more surgical and critical care procedures as growth drivers. - The report says home-based healthcare delivery, precise drug delivery systems, stricter infusion safety rules, oncology and chronic disease patient volumes and patient-centered care models will support growth through 2030. - Forecast trends include wider use of advanced infusion filtration in clinical settings, closed-system medication delivery, high-precision disposable infusion components, home intravenous therapy and stronger safeguards against air embolism and particulate contamination. - The report describes precision filter infusion sets as devices that filter infusion solutions before administration to improve safety and treatment accuracy. - The report says chemotherapy adoption is a major catalyst because the devices help control intravenous delivery of anti-cancer drugs. - Manchester’s Christie NHS Foundation Trust administered about 105,827 chemotherapy and immunotherapy sessions to more than 14,000 patients between April 2024 and March 2025. - The OECD projects the share of people aged 65 and older in OECD countries will rise from 18.5% in 2023 to 26.4% by 2050. - UK healthcare expenditure rose 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while government-funded healthcare reached $328 billion (£258 billion) in 2024.

Between the lines: - The market outlook points to a steady shift from basic infusion administration toward more controlled, contamination-resistant delivery systems. - Aging populations and rising chronic disease treatment needs appear to be reinforcing demand for safer, more precise infusion tools. - North America’s lead suggests adoption is strongest where safety regulation and medical-device uptake are already mature. - Asia-Pacific’s faster expected growth suggests the next phase of demand is likely to come from healthcare expansion and broader access to advanced treatment.

What's next: - The report expects home intravenous therapies to expand, which should increase demand for safer infusion control systems. - The report also expects more use of closed-system delivery and disposable precision components in hospitals. - The market’s regional momentum will likely depend on how quickly healthcare providers adopt stricter infusion-safety protocols and advanced filtration systems. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and hotspot infographics.

The bottom line: - Precision filter infusion sets are moving from a niche safety component to a broader part of modern infusion care, with the market on track for sustained growth through 2030.